Cardiac toxicity occurred in 8% after central and ultracentral lung SBRT
Symptomatic grade ≥2 cardiac toxicity occurred in 8% after central or ultracentral lung SBRT, typically developing more than one year after treatment.
Symptomatic grade ≥2 cardiac toxicity occurred in 8% after central or ultracentral lung SBRT, typically developing more than one year after treatment.
A maximum left anterior descending coronary artery dose of at least 12 Gy was independently associated with higher long-term cardiac risk.
A 40 Gy equivalent dose to at least 18% of the left anterior descending artery was associated with more than twofold risk of cardiac events.
The framework achieved 85.5% external-validation accuracy and reduced estimated review time from 822 hours to 2.3–4.8 hours.